Introduction: The aim of our study is to explore the relationship of rabbit anti-thymocyte globulin (R-ATG) on development of post-transplant lymphoproliferative disease (PTLD) and its aggressive forms (monomorphic PTLD and Hodgkin lymphoma) in renal transplant recipients.Methodology: All patients diagnosed with PTLD post-renal transplant in the United States' Organ Procurement and Transplantation Network from 2003 till 2013 and followed up till 2017 were retrospectively reviewed. Multi-variable logistic regression analysis assessed association of R-ATG to development of PTLD and its aggressive form.Results: Risk of developing PTLD post renal transplant is 1.35%. In comparison to interleukin-2 blocker induction therapy, R-ATG is associated with increased risk of development of PTLD (Odds Ratio = 1.48, confidence interval ranges from 1.04 to 2.11, p = .02) and is associated with higher risk of development of aggressive PTLD (Odds Ratio = 1.83, confidence interval ranges from 1.001 to 3.34, p = .04).Conclusion: We conclude that R-ATG induction is associated with a higher risk of PTLD and its aggressive form (monomorphic PTLD and Hodgkin lymphoma). Careful monitoring for development of PTLD in renal transplant recipients receiving R-ATG induction therapy is advised.

中文翻译：

---

肾移植人群中兔抗胸腺细胞球蛋白与PTLD发育及其侵袭性形式的关系。

简介：我们的研究目的是探讨兔抗胸腺细胞球蛋白（R-ATG）与肾移植受者移植后淋巴细胞增生性疾病（PTLD）的发展及其侵袭性形式（单形PTLD和霍奇金淋巴瘤）的关系。方法：回顾性分析了从2003年至2013年在美国器官采购和移植网络中诊断为PTLD的所有患者，并随访至2017年。多变量logistic回归分析评估了R-ATG与PTLD及其侵袭性形式的相关性。结果：肾移植后发生PTLD的风险为1.35％。与白介素2受体阻滞剂诱导疗法相比，R-ATG与PTLD发生风险增加相关（几率= 1.48，置信区间为1.04至2。11，p = .02），与发生侵袭性PTLD的风险较高相关（赔率= 1.83，置信区间为1.001至3.34，p = 0.04）。结论：我们得出结论认为R-ATG诱导与PTLD及其侵袭性形式（单形PTLD和霍奇金淋巴瘤）的风险较高。建议仔细监测接受R-ATG诱导治疗的肾移植受者中PTLD的发育。